Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15829971 | 0.91 | SLC6A4 (0.50) | HRH3SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL10150946 | 0.84 | SLC6A4 (0.51) | HRH3SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL10057699 | 0.84 | HRH3 (0.53) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13898673 | 0.84 | HRH3 (0.53) | HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5540295 | 0.83 | SLC6A2 (0.56) | HRH3SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL8025279 | 0.82 | HRH3 (0.69) | HRH3SLC6A4 | |
| SCHEMBL12127336 | 0.82 | SLC6A2 (0.67) | SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL22188038 | 0.81 | SLC6A2 (0.55) | HRH3SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL20069655 | 0.81 | SLC6A2 (0.55) | HRH3SLC6A2SLC6A4SLC6A3EPHX2 | |
| SCHEMBL5540288 | 0.81 | SLC6A2 (0.55) | HRH3SLC6A2SLC6A4SLC6A3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-7998954-B2 | Pyrimidodiazepinone derivative | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KYOWA HAKKO KIRIN CO., LTD (JP) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190775-A1 | PYRIMIDODIAZEPINONE DERIVATIVE | KCNJ1, KCNJ11, ADRA1D | HRH3 152/4885SLC6A2 181/4885SLC6A4 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.